Even though VEN targets BCL2 overexpression in AML patients, the monotherapy of the drug has minimal therapeutic properties, hinting a mechanism of intrinsic resistance of the leukemic cells to the drug (59). Here, BCL2 is linked to acute myeloid leukemia.